LEIDEN JEFFREY M
Known title: Executive ChairmanCIK: 0001242825
LEIDEN JEFFREY M's purchase track record
LEIDEN JEFFREY M has no open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/8/2026 | ODTX | $100K | +28.9% | pending | — |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Vertex Highlights Sickle Cell Gene Therapy and Hormone Disorder Expansion. Vertex Pharmaceuticals is advancing a gene therapy for sickle cell disease, which could broaden its treatment portfolio but faces access challenges. The company also signals a potential new growth area in hormone disorders, moving beyond cystic fibrosis. With earnings approaching, investors are watching how these developments affect the company’s outlook. The stock has risen above the market recently, reflecting positive sentiment.
Transaction History
| ODTX | ▲ Buy | Option Exercise | 2,963 | — | 5/11/2026 | View on chart |
| ODTX | ▼ Sell | Tax Withholding | 17 | $306 | 5/11/2026 | View on chart |
| ODTX | ▼ Sell | Other | 28,698 | — | 5/11/2026 | View on chart |
| ODTX | ▲ Buy | Open Market | 5,000 | $100K | 5/8/2026 | View on chart |
| VRTX | ▼ Sell | Tax Withholding | 3,547 | $1.7M | 2/24/2026 | View on chart |
| VRTX | ▼ Sell | Tax Withholding | 2,964 | $1.4M | 2/18/2026 | View on chart |
| VRTX | ▲ Buy | Grant | 8,269 | $0 | 2/17/2026 | View on chart |
| VRTX | ▲ Buy | Grant | 9,012 | $0 | 1/22/2026 | View on chart |
| VRTX | ▲ Buy | Option Exercise | 1 | $91 | 12/4/2025 | View on chart |
| VRTX | ▲ Buy | Option Exercise | 63,781 | $5.5M | 12/3/2025 | View on chart |
| VRTX | ▼ Sell | Open Market | 4,352 | $1.9M | 12/3/2025 | View on chart |
| VRTX | ▼ Sell | Open Market | 2,320 | $1.0M | 12/3/2025 | View on chart |
| VRTX | ▼ Sell | Open Market | 5,809 | $2.6M | 12/3/2025 | View on chart |
| VRTX | ▼ Sell | Open Market | 15,681 | $7.1M | 12/3/2025 | View on chart |
| VRTX | ▼ Sell | Open Market | 10,360 | $4.7M | 12/3/2025 | View on chart |
| VRTX | ▼ Sell | Open Market | 1,152 | $515K | 12/3/2025 | View on chart |
| VRTX | ▼ Sell | Open Market | 4,469 | $2.0M | 12/3/2025 | View on chart |
| VRTX | ▼ Sell | Open Market | 7,899 | $3.5M | 12/3/2025 | View on chart |
| VRTX | ▼ Sell | Open Market | 2,070 | $942K | 12/3/2025 | View on chart |
| VRTX | ▼ Sell | Open Market | 2,469 | $1.1M | 12/3/2025 | View on chart |
| VRTX | ▼ Sell | Open Market | 5,880 | $2.6M | 12/3/2025 | View on chart |
| VRTX | ▼ Sell | Open Market | 1,320 | $582K | 12/3/2025 | View on chart |
| VRTX | ▼ Sell | Open Market | 40 | $18K | 11/14/2025 | View on chart |
| VRTX | ▼ Sell | Open Market | 21,330 | $9.4M | 11/14/2025 | View on chart |
| VRTX | ▲ Buy | Option Exercise | 13,835 | $1.3M | 11/14/2025 | View on chart |
| VRTX | ▲ Buy | Option Exercise | 39,769 | $3.4M | 11/14/2025 | View on chart |
| VRTX | ▼ Sell | Open Market | 32,234 | $14.2M | 11/14/2025 | View on chart |
| VRTX | ▲ Buy | Option Exercise | 19,688 | $1.8M | 11/13/2025 | View on chart |
| VRTX | ▼ Sell | Open Market | 18,528 | $8.2M | 11/13/2025 | View on chart |
| VRTX | ▼ Sell | Open Market | 1,160 | $512K | 11/13/2025 | View on chart |
| VRTX | ▼ Sell | Tax Withholding | 6,066 | $2.8M | 2/14/2025 | View on chart |
| VRTX | ▼ Sell | Tax Withholding | 2,525 | $1.1M | 2/13/2025 | View on chart |
| VRTX | ▲ Buy | Grant | 7,209 | $0 | 2/12/2025 | View on chart |
| VRTX | ▲ Buy | Grant | 15,414 | $0 | 2/4/2025 | View on chart |
| VRTX | ▼ Sell | Open Market | 3,784 | $1.9M | 8/30/2024 | View on chart |
| VRTX | ▼ Sell | Tax Withholding | 4,118 | $1.7M | 2/20/2024 | View on chart |
| VRTX | ▼ Sell | Open Market | 4,655 | $2.0M | 2/15/2024 | View on chart |
| VRTX | ▼ Sell | Open Market | 4,356 | $1.8M | 2/14/2024 | View on chart |
| VRTX | ▼ Sell | Open Market | 737 | $309K | 2/13/2024 | View on chart |
| VRTX | ▼ Sell | Open Market | 647 | $272K | 2/12/2024 | View on chart |
| VRTX | ▼ Sell | Open Market | 2,009 | $842K | 2/12/2024 | View on chart |
| VRTX | ▼ Sell | Tax Withholding | 8,048 | $3.4M | 2/9/2024 | View on chart |
| VRTX | ▼ Sell | Tax Withholding | 2,698 | $1.1M | 2/8/2024 | View on chart |
| VRTX | ▲ Buy | Grant | 7,707 | $0 | 2/7/2024 | View on chart |
| VRTX | ▲ Buy | Grant | 10,464 | $0 | 2/6/2024 | View on chart |
| VRTX | ▲ Buy | Grant | 20,452 | $0 | 2/6/2024 | View on chart |
| VRTX | ▼ Sell | Open Market | 6,648 | $2.8M | 1/8/2024 | View on chart |
| VRTX | ▼ Sell | Open Market | 100 | $40K | 12/13/2023 | View on chart |
| VRTX | ▼ Sell | Open Market | 13,254 | $5.3M | 12/13/2023 | View on chart |
| VRTX | ▼ Sell | Open Market | 12,962 | $4.8M | 10/16/2023 | View on chart |
| VRTX | ▼ Sell | Open Market | 1,125 | $393K | 5/8/2023 | View on chart |
| VRTX | ▼ Sell | Open Market | 708 | $247K | 5/5/2023 | View on chart |
| VRTX | ▼ Sell | Open Market | 171 | $60K | 5/5/2023 | View on chart |
| VRTX | ▼ Sell | Open Market | 700 | $246K | 5/3/2023 | View on chart |
| VRTX | ▼ Sell | Open Market | 2,008 | $701K | 5/3/2023 | View on chart |
| VRTX | ▼ Sell | Open Market | 1,800 | $631K | 5/3/2023 | View on chart |
| VRTX | ▼ Sell | Open Market | 4,645 | $1.6M | 5/2/2023 | View on chart |
| VRTX | ▼ Sell | Open Market | 1,505 | $527K | 5/2/2023 | View on chart |
| VRTX | ▼ Sell | Open Market | 300 | $106K | 5/2/2023 | View on chart |
| VRTX | ▼ Sell | Tax Withholding | 13,730 | $4.0M | 2/24/2023 | View on chart |
| VRTX | ▼ Sell | Tax Withholding | 13,344 | $4.0M | 2/13/2023 | View on chart |
| VRTX | ▼ Sell | Tax Withholding | 3,578 | $1.1M | 2/2/2023 | View on chart |
| VRTX | ▲ Buy | Grant | 34,890 | $0 | 2/1/2023 | View on chart |
| VRTX | ▲ Buy | Grant | 31,462 | $0 | 2/1/2023 | View on chart |
| VRTX | ▲ Buy | Grant | 10,226 | $0 | 2/1/2023 | View on chart |
| VRTX | ▼ Sell | Open Market | 32,983 | $9.2M | 7/25/2022 | View on chart |
| VRTX | ▼ Sell | Open Market | 34,090 | $9.6M | 7/25/2022 | View on chart |
| VRTX | ▼ Sell | Open Market | 10,471 | $3.0M | 7/25/2022 | View on chart |
| VRTX | ▼ Sell | Open Market | 40,666 | $11.5M | 7/25/2022 | View on chart |
| VRTX | ▲ Buy | Option Exercise | 60,342 | $5.5M | 7/25/2022 | View on chart |
| VRTX | ▼ Sell | Open Market | 13,869 | $3.9M | 7/25/2022 | View on chart |
| VRTX | ▼ Sell | Open Market | 15,789 | $4.6M | 4/13/2022 | View on chart |
| VRTX | ▼ Sell | Tax Withholding | 12,141 | $2.8M | 2/24/2022 | View on chart |
| VRTX | ▼ Sell | Tax Withholding | 8,236 | $1.9M | 2/17/2022 | View on chart |
| VRTX | ▼ Sell | Tax Withholding | 6,279 | $1.5M | 2/2/2022 | View on chart |
| VRTX | ▲ Buy | Grant | 28,444 | $0 | 2/1/2022 | View on chart |
| VRTX | ▲ Buy | Grant | 20,928 | $0 | 2/1/2022 | View on chart |
| VRTX | ▲ Buy | Grant | 17,445 | $0 | 2/1/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
Odyssey Therapeutics to Present OD-001 Data at UEG Week 2026
Odyssey Therapeutics announced that it will present additional Phase 2a induction data for its drug OD-001 in ulcerative colitis at the UEG Week 2026 conference. This upcoming presentation provides new clinical information on the company's lead candidate. The stock is currently trading near its 52-week low, with an average analyst target price of $35.75.
Odyssey Therapeutics to Present OD-001 Data at UEG Week 2026. Odyssey Therapeutics announced that it will present additional Phase 2a induction data for its drug OD-001 in ulcerative colitis at the UEG Week 2026 conference. This upcoming presentation provides new clinical information on the company's lead candidate. The stock is currently trading near its 52-week low, with an average analyst target price of $35.75.